Rx-to-OTC switch guidelines recommended in Senate FDA reform report language.
This article was originally published in The Tan Sheet
Executive Summary
Rx-TO-OTC SWITCH GUIDELINES RECOMMENDED IN REPORT LANGUAGE accompanying Sen. Nancy Kassebaum's (R-Kan.) FDA reform bill (S 1477) filed with the Senate June 20. The report states that the Committee on Labor & Human Resources, which Kassebaum chairs, "expects that FDA, as part of its mission of...`facilitating the rapid and efficient availability of products subject to its regulation,' will establish appropriate procedures and policies, including performance standards, to expedite the review" of Rx-to-OTC switches.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning